Category Archives: Clinical Cardiology

There is a disproportionate representation of diverse racial and ethnic groups when compared to the over-representation of white counterparts in clinical trials. Since race and ethnicity are known to contribute to interindividual differences in drug exposure along with responses, the risk-benefit ratio is thus altered in certain populations. At the 14th American Association for Cancer Research (AACR) Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, held virtually on 68 October, the results of a simulated pancreatic cancer clinical trial screening process revealed that Black patients were significantly more likely to be excluded from pancreatic clinical trials than their white counterparts. Continue reading →

The event is hosted by the Department of Medicine, Division of Cardiology, University of Pennsylvania Health System in Philadelphia, Pennsylvania and the Division of Cardiology, The Mount Sinai Hospital in New York, New York () has said its flagshipPURE EPSystem technology will be featured in a live patient case streamed during the 16th Annual International Symposium on Ventricular Arrhythmias: Pathophysiology & Therapy (VT 2021), held virtually on October 15-16, 2021. VT 2021 has been developed to meet the educational needs of electrophysiologists, cardiologists, and other physicians and associated professionals interested in the pathophysiology and management of ventricular arrhythmias. The event is hosted by the Department of Medicine, Division of Cardiology, University of Pennsylvania Health System in Philadelphia, Pennsylvania and the Division of Cardiology, The Mount Sinai Hospital in New York, New York Continue reading →

The forum emphasised on exchange of knowledge on latest innovations and clinical trials by leaders in Interventional cardiology from both India and United States. Over 25 million heart failure cases worldwide and 8-10 million heart failure patients in India, which translates into 40% of global burden heart failure. Continue reading →

Introduction Cardiac output (CO) is the primary driver of blood pressure (BP) and is closely linked to BP. Patients with heart failure and low BP (HF-LBP) have increased rates of in- and out-of-hospital mortality. There are two important features in the pathophysiology of hospitalized patients with HF-LBP, namely congestion and low CO. Continue reading →

Its no secret that getting accepted into medical school is highly competitive, and for those who are admitted, making the choice of which school to attend can feel overwhelming. Hearing insights and advice directly from those who have successfully navigated the process and are currently thriving in medical school ahead of you, though, can be invaluable Continue reading →

National trial will study biomarkers that predict delayed recovery in children, teens Researchers at the University of Rochester Medical Center are part of a new collaborative project, led by the University of California, Los Angeles, to study concussions in children and teens. The project, which was awarded $10 million from the National Institute of Neurological Disorders and Stroke, will test ways to predict which kids will develop persistent symptoms after a concussion, so researchers can study how to help them recover faster Continue reading →

Scientific researches of scientists of the Department of Hospital Therapy of the Medical Institute in the field of cardiology are presented at an international conference. On October 7-9, 2021, Dubai (UAE) hosted the 12th Annual Conference of the Emirates Cardiological Society in collaboration with the American Heart Association Continue reading →

The more complicated a primary endpoint, the greater a puzzle it can be for clinicians to interpret the results. It's likely even tougher for patients, who don't help choose the events studied in clinical trials yet are increasingly sharing in the management decisions they influence Continue reading →

Previously reported benefits of alcohol intake for patients with cardiovascular disease appear to be partially mediated through modulation of stress-associated brain activity, a new study suggests. Continue reading →

SOUTH SAN FRANCISCO, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced three presentations at the American College of Cardiology 70th Annual Scientific Session & Expo (ACC.21) taking place online from May 15, 2021 - May 17, 2021. Included among these presentations will be a secondary analysis of GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure) assessing the effect of omecamtiv mecarbil on clinical outcomes in relationship to patient baseline ejection fraction, in a Late Breaking Clinical Trial session. Late Breaking Clinical Trial Session Title: 410-16 Impact of Ejection Fraction on the Therapeutic Effect of Omecamtiv Mecarbil In Patients with Heart Failure and Reduced Ejection Fraction: A Secondary Analysis From GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure) Presenter: John Teerlink, M.D., Professor of Medicine, University of California San Francisco, Director of Heart Failure, San Francisco Veterans Affairs Medical Center and Executive Committee Chair, GALACTIC-HF Date: May 17, 2021 Session Title: Late-Breaking Clinical Trials IV Session Time: 8:00 9:15 AM ET Presentation Time: 9:00 9:10 AM ET Poster Presentations The following posters will be available on demand for registered attendees beginning on May 15, 2021 at 8:00 AM ET. Continue reading →